The effects of melissa officinalis on depression and anxiety in type 2 diabetes patients with depression: a randomized double-blinded placebo-controlled clinical trial

Table 1 General characteristics of T2DM patients at baseline

Variable		HEMO (n = 23)	Placebo (n = 21)	p Value
Age (yr)		52.65 ± 6.14	54.19 ± 5.99	0.53^‡
Male/Female N (%)		9(39.1)/14(60.9)	10(47.6)/11(52.4)	0.57**
Duration of diabetes (yr)		6.26 ± 3.1	6.76 ± 4.47	0.66^‡
Hypolipidemic agents N (%)	Metformin	6 (26.1)	10 (47.6)	0.37**
	Metformin + Glibenclamide	14 (60.9)	10 (47.6)
	Metformin + Repaglinide	2 (8.7)	0 (00)
	Metformin + Glibenclamide + Repaglinide	1 (4.3)	1 (4.8)
Hypolipidemic agents N (%)	Atorvastatin	17 (73.9)	15 (71.4)	0.85**
Hypotensive agents N (%)	Losartan	10 (43.5)	10 (47.6)	0.78**

Values are presented as mean ± standard deviation or n (%). P-valuses based on: ^‡Independent t test; t; ** Fisher’s exact test
HEMO hydroalcoholic extract of M. officinalis, WC Waist circumference

ISSN: 2662-7671